Klotho Neurosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KLTO research report →
About the company
Klotho Neurosciences, Inc. operates as a biopharmaceutical enterprise focused on devising medical treatments for various conditions, including cancer, cardiovascular ailments, and neurodegenerative disorders. Their leading gene therapy assets encompass AMI-101, which is designed for the management or prevention of Alzheimer's disease, and AMI-202, aimed at treating or averting amyotrophic lateral sclerosis.
- CEO
- Joseph A. Sinkule
- IPO
- 2022
- Employees
- 3
- HQ
- Omaha, NE, US
Price Chart
- Market Cap
- $20.08M
- P/E
- -0.67
- P/S
- 0.00
- P/B
- 0.41
- EV/EBITDA
- -0.35
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -108.82%
- ROIC
- -25.34%
- Revenue
- $0 · 0.00%
- Net Income
- $-10,551,674 · -71.56%
- EPS
- $-0.22 · 31.25%
- Op Income
- $-7,146,265
- FCF YoY
- -90.82%
- 52W High
- $3.91
- 52W Low
- $0.11
- 50D MA
- $0.34
- 200D MA
- $0.63
- Beta
- 2.23
- Avg Volume
- 3.23M
Get TickerSpark's AI analysis on KLTO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 4, 26 | LeBlanc Jeff | other | 2,500,000 |
| Mar 4, 26 | El-Dada Riad Hussein | other | 350,000 |
| Mar 4, 26 | ZENTMAN SAMUEL M | other | 350,000 |
| Mar 4, 26 | Hirschman Shalom | other | 350,000 |
| Mar 4, 26 | McGarity Jon | other | 350,000 |
| Mar 4, 26 | SINKULE JOSEPH | other | 2,500,000 |
| Dec 10, 25 | McGarity Jon | other | 20,000 |
| Dec 10, 25 | ZENTMAN SAMUEL M | other | 20,000 |
| Dec 10, 25 | El-Dada Riad Hussein | other | 20,000 |
| Sep 25, 25 | SINKULE JOSEPH | other | 400,000 |
Our KLTO coverage
Recent articles, reports, and earnings notes.
No research on KLTO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KLTO report →Similar companies
Peers in the same neighborhood.